| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 25 | 2019 | 173 | 8.600 |
Why?
|
| Geriatric Assessment | 28 | 2019 | 355 | 5.960 |
Why?
|
| Neoplasms | 32 | 2019 | 610 | 4.420 |
Why?
|
| Geriatrics | 12 | 2019 | 94 | 3.630 |
Why?
|
| Medical Oncology | 12 | 2019 | 70 | 2.680 |
Why?
|
| Antineoplastic Agents | 14 | 2018 | 546 | 2.260 |
Why?
|
| Aged | 73 | 2019 | 9487 | 2.100 |
Why?
|
| Comorbidity | 19 | 2018 | 540 | 1.550 |
Why?
|
| Aged, 80 and over | 38 | 2018 | 3717 | 1.480 |
Why?
|
| Humans | 85 | 2019 | 29093 | 1.410 |
Why?
|
| Breast Neoplasms | 8 | 2018 | 666 | 1.340 |
Why?
|
| Activities of Daily Living | 10 | 2019 | 238 | 1.340 |
Why?
|
| Aging | 9 | 2019 | 881 | 1.290 |
Why?
|
| Age Factors | 23 | 2019 | 1108 | 1.280 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2016 | 22 | 1.200 |
Why?
|
| Cognition | 7 | 2018 | 526 | 1.150 |
Why?
|
| Hematologic Neoplasms | 2 | 2017 | 28 | 1.060 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2018 | 163 | 0.930 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2018 | 401 | 0.920 |
Why?
|
| Polypharmacy | 4 | 2018 | 20 | 0.880 |
Why?
|
| Female | 53 | 2019 | 18164 | 0.860 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 207 | 0.860 |
Why?
|
| Disease Management | 3 | 2019 | 114 | 0.830 |
Why?
|
| Hematologic Diseases | 2 | 2018 | 23 | 0.800 |
Why?
|
| Quality of Life | 13 | 2018 | 816 | 0.730 |
Why?
|
| Male | 45 | 2019 | 17807 | 0.720 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 93 | 0.720 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 50 | 0.720 |
Why?
|
| Prognosis | 10 | 2019 | 1362 | 0.700 |
Why?
|
| Depression | 4 | 2018 | 380 | 0.690 |
Why?
|
| Hyperglycemia | 2 | 2018 | 82 | 0.690 |
Why?
|
| Carboplatin | 2 | 2018 | 40 | 0.690 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 73 | 0.650 |
Why?
|
| Paclitaxel | 1 | 2018 | 50 | 0.650 |
Why?
|
| Treatment Outcome | 12 | 2019 | 3099 | 0.640 |
Why?
|
| Middle Aged | 24 | 2018 | 10829 | 0.610 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 298 | 0.610 |
Why?
|
| Accidental Falls | 2 | 2018 | 204 | 0.610 |
Why?
|
| Hospitalization | 4 | 2018 | 417 | 0.600 |
Why?
|
| Health Services for the Aged | 2 | 2015 | 25 | 0.600 |
Why?
|
| Risk Assessment | 5 | 2018 | 1305 | 0.600 |
Why?
|
| Patient Care Management | 1 | 2016 | 17 | 0.590 |
Why?
|
| Prospective Studies | 17 | 2019 | 2019 | 0.590 |
Why?
|
| Physician's Role | 1 | 2016 | 38 | 0.580 |
Why?
|
| Multiple Myeloma | 3 | 2018 | 15 | 0.570 |
Why?
|
| Blood Glucose | 1 | 2018 | 466 | 0.560 |
Why?
|
| Cognition Disorders | 3 | 2015 | 390 | 0.540 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 709 | 0.530 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 384 | 0.520 |
Why?
|
| Physical Fitness | 1 | 2014 | 119 | 0.480 |
Why?
|
| Tamoxifen | 1 | 2013 | 48 | 0.470 |
Why?
|
| Risk Factors | 12 | 2019 | 3531 | 0.460 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 65 | 0.440 |
Why?
|
| Social Support | 4 | 2016 | 163 | 0.440 |
Why?
|
| Exercise | 5 | 2019 | 591 | 0.420 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 125 | 0.420 |
Why?
|
| Medication Adherence | 1 | 2013 | 144 | 0.410 |
Why?
|
| Survival Rate | 6 | 2018 | 795 | 0.400 |
Why?
|
| Disability Evaluation | 4 | 2016 | 211 | 0.400 |
Why?
|
| Retrospective Studies | 10 | 2018 | 3111 | 0.380 |
Why?
|
| Hand Strength | 2 | 2010 | 85 | 0.380 |
Why?
|
| Exercise Therapy | 1 | 2013 | 229 | 0.380 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 1013 | 0.370 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 525 | 0.370 |
Why?
|
| Walking | 2 | 2010 | 177 | 0.360 |
Why?
|
| Survivors | 3 | 2016 | 145 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2018 | 83 | 0.350 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 153 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 464 | 0.310 |
Why?
|
| Colorectal Neoplasms | 3 | 2015 | 208 | 0.300 |
Why?
|
| Heart Ventricles | 2 | 2018 | 107 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1379 | 0.300 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 637 | 0.290 |
Why?
|
| United States | 11 | 2018 | 3630 | 0.280 |
Why?
|
| Mobility Limitation | 2 | 2018 | 187 | 0.280 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2005 | 2 | 0.280 |
Why?
|
| Nasal Cavity | 1 | 2005 | 5 | 0.280 |
Why?
|
| Nose Neoplasms | 1 | 2005 | 4 | 0.280 |
Why?
|
| Adult | 12 | 2018 | 8420 | 0.280 |
Why?
|
| Logistic Models | 4 | 2015 | 727 | 0.270 |
Why?
|
| Curriculum | 2 | 2017 | 196 | 0.260 |
Why?
|
| Stroke Volume | 2 | 2018 | 278 | 0.260 |
Why?
|
| Mental Health | 2 | 2016 | 104 | 0.260 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 203 | 0.250 |
Why?
|
| Longitudinal Studies | 7 | 2018 | 720 | 0.240 |
Why?
|
| Cohort Studies | 7 | 2019 | 1687 | 0.240 |
Why?
|
| Nutrition Assessment | 2 | 2016 | 54 | 0.230 |
Why?
|
| Radiotherapy, Conformal | 1 | 2011 | 19 | 0.210 |
Why?
|
| United States Food and Drug Administration | 2 | 2018 | 44 | 0.200 |
Why?
|
| SEER Program | 2 | 2019 | 32 | 0.200 |
Why?
|
| Anthracyclines | 2 | 2018 | 51 | 0.200 |
Why?
|
| Frail Elderly | 2 | 2017 | 65 | 0.190 |
Why?
|
| Motor Activity | 2 | 2013 | 310 | 0.190 |
Why?
|
| Societies, Medical | 2 | 2018 | 149 | 0.190 |
Why?
|
| Inpatients | 2 | 2018 | 64 | 0.180 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 169 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 222 | 0.180 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2018 | 136 | 0.180 |
Why?
|
| Risk | 3 | 2016 | 289 | 0.180 |
Why?
|
| Neoplasm Staging | 5 | 2017 | 436 | 0.180 |
Why?
|
| Morbidity | 1 | 2019 | 91 | 0.170 |
Why?
|
| Anemia | 2 | 2017 | 55 | 0.170 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 1356 | 0.170 |
Why?
|
| Behavioral Symptoms | 1 | 2018 | 3 | 0.170 |
Why?
|
| Resilience, Psychological | 1 | 2018 | 15 | 0.160 |
Why?
|
| Hearing Loss | 1 | 2018 | 19 | 0.160 |
Why?
|
| Vision Disorders | 1 | 2018 | 20 | 0.160 |
Why?
|
| Fluorouracil | 2 | 2017 | 73 | 0.160 |
Why?
|
| Patient Preference | 1 | 2018 | 38 | 0.160 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 11 | 0.160 |
Why?
|
| Hematology | 1 | 2017 | 5 | 0.160 |
Why?
|
| Salvage Therapy | 2 | 2015 | 118 | 0.160 |
Why?
|
| Cardiac Volume | 1 | 2017 | 11 | 0.150 |
Why?
|
| Mastectomy | 1 | 2017 | 59 | 0.150 |
Why?
|
| Exercise Movement Techniques | 1 | 2016 | 3 | 0.150 |
Why?
|
| Oncology Service, Hospital | 1 | 2016 | 4 | 0.150 |
Why?
|
| Career Mobility | 1 | 2017 | 14 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 441 | 0.150 |
Why?
|
| Leukemia | 1 | 2017 | 36 | 0.150 |
Why?
|
| Education | 1 | 2016 | 30 | 0.150 |
Why?
|
| Medicine | 1 | 2017 | 30 | 0.150 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 281 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 1 | 2016 | 16 | 0.150 |
Why?
|
| Diet | 1 | 2019 | 354 | 0.150 |
Why?
|
| Intensive Care Units | 1 | 2017 | 118 | 0.150 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 53 | 0.140 |
Why?
|
| Decision Making | 2 | 2018 | 180 | 0.140 |
Why?
|
| Nutrition Disorders | 1 | 2016 | 12 | 0.140 |
Why?
|
| Transplantation, Homologous | 2 | 2015 | 113 | 0.140 |
Why?
|
| Physical Examination | 1 | 2016 | 82 | 0.140 |
Why?
|
| Life Expectancy | 1 | 2016 | 16 | 0.140 |
Why?
|
| Research | 1 | 2016 | 72 | 0.140 |
Why?
|
| Time Factors | 4 | 2017 | 2001 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 131 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 194 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 366 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2016 | 168 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2017 | 153 | 0.130 |
Why?
|
| Drug Dosage Calculations | 1 | 2015 | 7 | 0.130 |
Why?
|
| Medicaid | 2 | 2012 | 83 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 47 | 0.130 |
Why?
|
| Clinical Competence | 1 | 2017 | 307 | 0.130 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1131 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2015 | 68 | 0.120 |
Why?
|
| Research Design | 1 | 2016 | 286 | 0.120 |
Why?
|
| North Carolina | 3 | 2018 | 1423 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 301 | 0.120 |
Why?
|
| Deoxycytidine | 1 | 2014 | 63 | 0.120 |
Why?
|
| Women's Health | 1 | 2016 | 226 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2012 | 263 | 0.120 |
Why?
|
| Portraits as Topic | 1 | 2013 | 4 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2016 | 239 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 24 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2014 | 274 | 0.120 |
Why?
|
| Azacitidine | 1 | 2013 | 28 | 0.120 |
Why?
|
| CA-125 Antigen | 1 | 2013 | 6 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 787 | 0.120 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2013 | 7 | 0.120 |
Why?
|
| Prevalence | 4 | 2018 | 896 | 0.120 |
Why?
|
| Affective Symptoms | 1 | 2013 | 16 | 0.110 |
Why?
|
| Anxiety | 1 | 2014 | 159 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 9 | 0.110 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 17 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2013 | 59 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2013 | 130 | 0.110 |
Why?
|
| Heart Failure | 1 | 2018 | 568 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 87 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 379 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 359 | 0.110 |
Why?
|
| Adiposity | 1 | 2013 | 191 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2012 | 231 | 0.110 |
Why?
|
| Colonoscopy | 1 | 2012 | 41 | 0.110 |
Why?
|
| Nonprescription Drugs | 1 | 2012 | 18 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 2108 | 0.110 |
Why?
|
| Plant Preparations | 1 | 2012 | 21 | 0.110 |
Why?
|
| Inflammation | 1 | 2015 | 507 | 0.110 |
Why?
|
| Nursing Assessment | 1 | 2011 | 11 | 0.100 |
Why?
|
| African Americans | 1 | 2019 | 1373 | 0.100 |
Why?
|
| Postmenopause | 1 | 2013 | 397 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2012 | 74 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 68 | 0.100 |
Why?
|
| Extremities | 1 | 2011 | 48 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 63 | 0.100 |
Why?
|
| Sarcoma | 1 | 2011 | 56 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2012 | 170 | 0.090 |
Why?
|
| Poverty | 1 | 2011 | 99 | 0.090 |
Why?
|
| Mass Screening | 1 | 2012 | 223 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 1 | 2013 | 241 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 374 | 0.090 |
Why?
|
| Disabled Persons | 1 | 2010 | 83 | 0.090 |
Why?
|
| Heart Failure, Diastolic | 1 | 2009 | 15 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 871 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2009 | 67 | 0.080 |
Why?
|
| Mentors | 1 | 2008 | 29 | 0.080 |
Why?
|
| Obesity | 1 | 2015 | 1063 | 0.080 |
Why?
|
| Faculty, Medical | 1 | 2008 | 69 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 120 | 0.080 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 78 | 0.070 |
Why?
|
| Algorithms | 1 | 2009 | 462 | 0.070 |
Why?
|
| Body Composition | 2 | 2019 | 365 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2009 | 348 | 0.060 |
Why?
|
| Remission Induction | 2 | 2015 | 78 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 518 | 0.060 |
Why?
|
| Linear Models | 2 | 2015 | 426 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2019 | 865 | 0.060 |
Why?
|
| Incidence | 2 | 2015 | 1119 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2019 | 29 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2018 | 8 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 133 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2018 | 10 | 0.040 |
Why?
|
| Fatigue | 1 | 2018 | 68 | 0.040 |
Why?
|
| Vomiting | 1 | 2018 | 24 | 0.040 |
Why?
|
| Nausea | 1 | 2018 | 49 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 62 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 77 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2019 | 159 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2018 | 66 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 48 | 0.040 |
Why?
|
| Canada | 1 | 2017 | 48 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 23 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 9 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 20 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Health Behavior | 1 | 2019 | 214 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 23 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 19 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 273 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 32 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 56 | 0.040 |
Why?
|
| Sulfides | 1 | 2017 | 24 | 0.040 |
Why?
|
| Caprylates | 1 | 2017 | 25 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2017 | 34 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 42 | 0.040 |
Why?
|
| Camptothecin | 1 | 2017 | 48 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2017 | 40 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2018 | 126 | 0.040 |
Why?
|
| Creatine | 1 | 2016 | 5 | 0.040 |
Why?
|
| Mind-Body Therapies | 1 | 2016 | 11 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 90 | 0.040 |
Why?
|
| Life Style | 1 | 2019 | 364 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 64 | 0.040 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2016 | 7 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 14 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 102 | 0.040 |
Why?
|
| Consensus | 1 | 2016 | 68 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2015 | 42 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 287 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 146 | 0.030 |
Why?
|
| Asparaginase | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mitoxantrone | 1 | 2015 | 17 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 191 | 0.030 |
Why?
|
| DNA Helicases | 1 | 1995 | 5 | 0.030 |
Why?
|
| Cytarabine | 1 | 2015 | 52 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 1995 | 20 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 1995 | 31 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2015 | 136 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 293 | 0.030 |
Why?
|
| DNA Repair | 1 | 1995 | 50 | 0.030 |
Why?
|
| Body Weight | 1 | 2016 | 290 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 641 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2015 | 225 | 0.030 |
Why?
|
| Escherichia coli | 1 | 1995 | 82 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 246 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 235 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 232 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 257 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 200 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 142 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 440 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2015 | 369 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 10 | 0.030 |
Why?
|
| Body Fat Distribution | 1 | 2013 | 34 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 368 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2013 | 129 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2013 | 58 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 572 | 0.030 |
Why?
|
| Cisplatin | 1 | 2013 | 69 | 0.030 |
Why?
|
| DNA Damage | 1 | 2013 | 88 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 326 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 141 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 2402 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2009 | 30 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 863 | 0.020 |
Why?
|
| Conjugation, Genetic | 1 | 1995 | 1 | 0.010 |
Why?
|
| RecQ Helicases | 1 | 1995 | 1 | 0.010 |
Why?
|
| Methyl Methanesulfonate | 1 | 1995 | 3 | 0.010 |
Why?
|
| Adenosine Triphosphatases | 1 | 1995 | 11 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1995 | 14 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1995 | 36 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1995 | 46 | 0.010 |
Why?
|